Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP.
Sign Up to like & getrecommendations! Published in 2017 at "Biochimie"
DOI: 10.1016/j.biochi.2017.01.010
Abstract: Human plasma kallikrein (huPK) potentiates platelet responses to subthreshold doses of ADP, although huPK itself, does not induce platelet aggregation. In the present investigation, we observe that huPK pretreatment of platelets potentiates ADP-induced platelet activation… read more here.
Keywords: doses adp; plasma kallikrein; subthreshold doses; hupk ... See more keywords
Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2019.01.040
Abstract: Apelins are human peptide hormones with various physiological activities, including the moderation of cardiovascular, renal, metabolic and neurological function. Their potency is dependent on and limited by proteolytic degradation in the circulatory system. Here we… read more here.
Keywords: apelin analogs; pressure lowering; blood pressure; plasma kallikrein ... See more keywords
Discovery and development of plasma kallikrein inhibitors for multiple diseases.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2020.112137
Abstract: Plasma kallikrein (PKal) belongs to the family of trypsin-like serine proteases. The expression of PKal is associated with multiple physiological systems or pathways such as coagulation pathway, platelet aggregation process, kallikrein-kinin system, renin-angiotensin system and… read more here.
Keywords: kallikrein; discovery development; pkal inhibitors; plasma kallikrein ... See more keywords
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medicinal Chemistry"
DOI: 10.1021/acs.jmedchem.2c00921
Abstract: Hereditary angioedema (HAE) is a rare genetic disorder in which patients experience sudden onset of swelling in various locations of the body. HAE is associated with uncontrolled plasma kallikrein (PKa) enzyme activity and generation of… read more here.
Keywords: plasma kallikrein; small molecule; hereditary angioedema; potential oral ... See more keywords
Inhibition of plasma kallikrein–kinin system to alleviate renal injury and arthritis symptoms in rats with adjuvant-induced arthritis
Sign Up to like & getrecommendations! Published in 2018 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2017.1418883
Abstract: Abstract Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease. Impairment of kidney functions in RA was observed. However, the mechanism of kidney injury of RA has not been clear. Plasma kallikrein–kinin system (KKS)… read more here.
Keywords: kallikrein kinin; arthritis; injury; plasma kallikrein ... See more keywords
Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13233
Abstract: Hereditary angioedema (HAE) is an autosomal dominant disorder characterized by recurrent episodes of swelling of the skin, larynx, gastrointestinal tract, genitals, and extremities that can be disruptive to patient quality of life. Dysregulation of plasma… read more here.
Keywords: plasma kallikrein; hereditary angioedema; modeling simulations; population pharmacokinetic ... See more keywords
Lanadelumab to treat hereditary angioedema.
Sign Up to like & getrecommendations! Published in 2019 at "Drugs of today"
DOI: 10.1358/dot.2019.55.7.2985293
Abstract: Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacks of hereditary angioedema (HAE). HAE is caused by SERPING1 gene mutations resulting in decreased or dysfunctional plasma protease C1 inhibitor (C1-INH)… read more here.
Keywords: treat hereditary; plasma kallikrein; hereditary angioedema; lanadelumab treat ... See more keywords